Qiagen (1K) | Hold (Not Rated) | Visibility remains the missing piece

Research evidence excerpt

Qiagen (1K) | Hold (Not Rated) | Visibility remains the missing piece

Qiagen Hold | Target Price: EUR34.00

Company at a glance: the most molecular-focused franchise

Qiagen is a global leader in molecular diagnostics and life science tools, offering end-to-end

“sample to insight” solutions that span sample preparation, molecular testing, and data

analysis. Founded in Germany but headquartered in the Netherlands, and listed in both

Germany and the US, the company operates in more than 25 countries and serves a broad

customer base across clinical laboratories, academia, and the pharmaceutical and biotech

industries.

Its business is split between Molecular Diagnostics (c.55% of sales), focused on clinical

testing in infectious diseases, and Life Sciences (c.45%), which supports research, drug

discovery, and biomarker development.

The company’s portfolio is built around four main product groups: sample technologies,

diagnostic solutions, PCR technologies, and genomics/NGS.

Sample technologies (c. 30% of sales) form the backbone of its workflows, enabling the

preparation of biological material for analysis, while diagnostic solutions (c. 40%) represent

the largest segment, providing integrated testing platforms such as QuantiFERON for

tuberculosis and QIAstat-Dx for syndromic testing.

PCR technologies (c. 15%) and genomics/NGS (c. 10%) support the detection, quantification,

and large-scale analysis of genetic material, positioning Qiagen at the core of modern

molecular diagnostics and precision medicine.

Qiagen business overview

Qiagen is a leading global provided of diagnostics solutions in molecular biology, serving both life

science and molecular diagnostic markets. With a 100% free float, founded in 1984 in Germany,